[go: up one dir, main page]

DK200000133U3 - Ny farmaceutisk formulering - Google Patents

Ny farmaceutisk formulering Download PDF

Info

Publication number
DK200000133U3
DK200000133U3 DK200000133U DKBA200000133U DK200000133U3 DK 200000133 U3 DK200000133 U3 DK 200000133U3 DK 200000133 U DK200000133 U DK 200000133U DK BA200000133 U DKBA200000133 U DK BA200000133U DK 200000133 U3 DK200000133 U3 DK 200000133U3
Authority
DK
Denmark
Prior art keywords
amoxycillin
release
tablet
potassium clavulanate
formulation
Prior art date
Application number
DK200000133U
Other languages
Danish (da)
English (en)
Inventor
Kevin Storm
Creighton Conley
John Roush
Original Assignee
Beecham Pharm Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27383840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200000133(U3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Pharm Pte Ltd filed Critical Beecham Pharm Pte Ltd
Application granted granted Critical
Publication of DK200000133U3 publication Critical patent/DK200000133U3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DK200000133U 1999-04-13 2000-04-11 Ny farmaceutisk formulering DK200000133U3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12907499P 1999-04-13 1999-04-13
US15072799P 1999-08-25 1999-08-25
US15981399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
DK200000133U3 true DK200000133U3 (da) 2000-07-28

Family

ID=27383840

Family Applications (3)

Application Number Title Priority Date Filing Date
DK200000133U DK200000133U3 (da) 1999-04-13 2000-04-11 Ny farmaceutisk formulering
DK00303033T DK1044680T3 (da) 1999-04-13 2000-04-11 Hidtil ukendt behandlingsmetode med et højt dosisregimen af amoxycillin og kaliumclavulanat
DK200000602A DK200000602A (da) 1999-04-13 2000-04-11 Ny fremgangsåde til behandling

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK00303033T DK1044680T3 (da) 1999-04-13 2000-04-11 Hidtil ukendt behandlingsmetode med et højt dosisregimen af amoxycillin og kaliumclavulanat
DK200000602A DK200000602A (da) 1999-04-13 2000-04-11 Ny fremgangsåde til behandling

Country Status (44)

Country Link
EP (4) EP1270005A3 (fi)
JP (2) JP4880125B2 (fi)
KR (1) KR100634937B1 (fi)
CN (1) CN100382782C (fi)
AP (1) AP1806A (fi)
AR (1) AR031068A1 (fi)
AT (2) ATE242629T1 (fi)
AU (1) AU767177B2 (fi)
BE (2) BE1013309A5 (fi)
BG (1) BG65006B1 (fi)
BR (1) BRPI0009719B8 (fi)
CA (1) CA2366304C (fi)
CO (1) CO5170471A1 (fi)
CZ (1) CZ298801B6 (fi)
DE (3) DE60003255T2 (fi)
DK (3) DK200000133U3 (fi)
DZ (1) DZ3150A1 (fi)
EA (1) EA004310B1 (fi)
ES (2) ES2202004T3 (fi)
FI (2) FI20000863L (fi)
FR (1) FR2792198A1 (fi)
GB (1) GB2351661B (fi)
GR (1) GR1003560B (fi)
HU (1) HU229097B1 (fi)
IE (1) IE20000271A1 (fi)
IL (2) IL145580A0 (fi)
IT (1) ITMI20000788A1 (fi)
MA (1) MA25352A1 (fi)
MX (1) MXPA01010377A (fi)
MY (1) MY119953A (fi)
NL (2) NL1014914C1 (fi)
NO (1) NO329694B1 (fi)
NZ (1) NZ514575A (fi)
OA (1) OA11926A (fi)
PE (1) PE20010053A1 (fi)
PL (1) PL197448B1 (fi)
PT (2) PT102450B (fi)
RO (1) RO120817B1 (fi)
SE (1) SE0001330L (fi)
SI (2) SI20304A (fi)
SK (1) SK285140B6 (fi)
TR (1) TR200102963T2 (fi)
TW (1) TWI235067B (fi)
WO (1) WO2000061116A2 (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030392A3 (en) * 2000-10-12 2003-05-15 Beecham Pharm Pte Ltd Formulation containing amoxicillin

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
PT862431E (pt) 1995-09-07 2002-04-29 Smithkline Beecham Plc Utilizacao de uma formulacao farmaceutica pediatrica que compreende amoxicilina e clavulanato
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
AU2002320309B2 (en) 2001-07-06 2007-07-12 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
AU2003220689A1 (en) * 2002-04-10 2003-10-27 Miller, Fred H Multi-phase, multi-compartment capsular system
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1541129A1 (en) * 2003-12-12 2005-06-15 Cimex AG Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005099672A1 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EP1880716A1 (en) * 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
AU2006349402A1 (en) * 2006-10-10 2008-04-17 Penwest Pharmaceuticals Co. Robust sustained release formulations
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
MX394829B (es) * 2015-04-07 2025-03-24 Church & Dwight Co Inc Composiciones gomosas de multicomponentes con nucleo suave.
CN109394718B (zh) * 2018-11-15 2021-04-27 石药集团中诺药业（石家庄）有限公司 一种阿莫西林分散片及其制备方法
CN110051637A (zh) * 2019-05-21 2019-07-26 葵花药业集团北京药物研究院有限公司 阿莫西林克拉维酸钾制剂及其制备方法
WO2023208241A1 (zh) * 2022-04-29 2023-11-02 越洋医药开发(广州)有限公司 一种吡非尼酮持续性释放口服固体制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008905B1 (en) * 1978-09-06 1983-02-16 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
EP1034784A3 (en) * 1993-01-22 2001-06-27 Smithkline Beecham Plc Pharmaceutical formulations containing clavulanic acid and an antibacterial agent
GB9311030D0 (en) * 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) * 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
PT862431E (pt) * 1995-09-07 2002-04-29 Smithkline Beecham Plc Utilizacao de uma formulacao farmaceutica pediatrica que compreende amoxicilina e clavulanato
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
SK110299A3 (en) * 1997-02-14 2000-08-14 Smithkline Beecham Lab Pharmaceutical formulations comprising amoxocyllin and clavulanate, preparation method and use thereof
EE9900396A (et) * 1997-03-11 2000-04-17 Almag Al Meetod ning seade metallide katmiseks
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
KR20000076329A (ko) * 1997-03-25 2000-12-26 다케다 야쿠힌 고교 가부시키가이샤 위장 점막 부착성 약제 조성물
JP3746901B2 (ja) * 1997-10-15 2006-02-22 ユニ・チャーム株式会社 開閉自在容器
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
US6225304B1 (en) * 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030392A3 (en) * 2000-10-12 2003-05-15 Beecham Pharm Pte Ltd Formulation containing amoxicillin

Also Published As

Publication number Publication date
BG65006B1 (bg) 2006-12-29
DK200000602A (da) 2000-10-14
BR0009719A (pt) 2002-01-08
KR100634937B1 (ko) 2006-10-17
TR200102963T2 (tr) 2002-02-21
NL1014914C1 (nl) 2000-10-16
ES2190692B1 (es) 2004-11-16
JP4880125B2 (ja) 2012-02-22
WO2000061116A3 (en) 2001-02-01
GB0008923D0 (en) 2000-05-31
SE0001330D0 (sv) 2000-04-11
FI20000863A7 (fi) 2000-10-13
NO20001870D0 (no) 2000-04-11
BG104329A (en) 2001-11-30
NZ514575A (en) 2004-05-28
CA2366304C (en) 2004-06-29
NO329694B1 (no) 2010-12-06
JP2011256180A (ja) 2011-12-22
EP1044680B1 (en) 2003-06-11
AP2001002284A0 (en) 2001-12-31
FI20000863L (fi) 2000-10-13
CN100382782C (zh) 2008-04-23
FI4823U1 (fi) 2001-02-16
PT102450B (pt) 2003-09-30
CN1382040A (zh) 2002-11-27
DE60003255D1 (de) 2003-07-17
NO20001870L (no) 2000-10-16
PT1044680E (pt) 2003-10-31
FR2792198A1 (fr) 2000-10-20
AR031068A1 (es) 2003-09-10
AP1806A (en) 2007-12-14
ATE242629T1 (de) 2003-06-15
ES2190692A1 (es) 2003-08-01
BRPI0009719B8 (pt) 2021-05-25
MY119953A (en) 2005-08-30
KR20020015312A (ko) 2002-02-27
MA25352A1 (fr) 2001-12-31
PL339591A1 (en) 2000-10-23
CZ298801B6 (cs) 2008-02-06
AU5702000A (en) 2000-11-14
FIU20000164U0 (fi) 2000-04-11
HUP0001471A3 (en) 2001-10-29
EP1270005A2 (en) 2003-01-02
BE1012733A6 (fr) 2001-02-06
GB2351661B (en) 2001-10-10
ITMI20000788A0 (it) 2000-04-11
CO5170471A1 (es) 2002-06-27
ES2202004T3 (es) 2004-04-01
EP1269996A1 (en) 2003-01-02
SK5342000A3 (en) 2000-11-07
HK1032741A1 (en) 2001-08-03
HU0001471D0 (en) 2000-06-28
RO120817B1 (ro) 2006-08-30
SI20304A (sl) 2001-02-28
CZ20001311A3 (cs) 2000-11-15
GB2351661A (en) 2001-01-10
NL1014915A1 (nl) 2000-10-16
IL145580A0 (en) 2002-11-10
AU767177B2 (en) 2003-11-06
CA2366304A1 (en) 2000-10-19
DK1044680T3 (da) 2003-09-29
IE20000271A1 (en) 2001-04-04
DZ3150A1 (fr) 2000-10-19
HUP0001471A2 (en) 2001-03-28
NL1014915C2 (nl) 2001-02-12
IL145580A (en) 2007-05-15
EA200101075A1 (ru) 2002-04-25
JP2002541187A (ja) 2002-12-03
DE20006626U1 (de) 2000-10-19
SE0001330L (sv) 2000-10-14
OA11926A (en) 2006-04-12
DE10017883A1 (de) 2000-10-26
DE60003255T2 (de) 2004-05-06
FI20000863A0 (fi) 2000-04-11
GR1003560B (el) 2001-03-16
EP1044680A1 (en) 2000-10-18
PT102450A (pt) 2001-02-01
TWI235067B (en) 2005-07-01
PL197448B1 (pl) 2008-03-31
SK285140B6 (sk) 2006-07-07
BR0009719B1 (pt) 2014-09-30
WO2000061116A2 (en) 2000-10-19
EP1270005A3 (en) 2006-05-17
AT4327U1 (de) 2001-06-25
ITMI20000788A1 (it) 2001-10-11
MXPA01010377A (es) 2002-10-23
SI1044680T1 (en) 2003-12-31
EA004310B1 (ru) 2004-02-26
EP1269997A1 (en) 2003-01-02
BE1013309A5 (fr) 2001-11-06
PE20010053A1 (es) 2001-03-10
HU229097B1 (en) 2013-07-29

Similar Documents

Publication Publication Date Title
DK200000133U3 (da) Ny farmaceutisk formulering
US6294199B1 (en) Method of treating a bacterial infection comprising administering amoxycillin
US6783773B1 (en) Composition comprising amoxicillin and potassium clavulanate
US6746692B2 (en) Modified release pharmaceutical formulation comprising amoxycillin
GB2365337A (en) Amoxycillin and potassium clavulanate high dosage regimen
HK1052639A (en) Unit dosage comprising amoxicillin and clavulanate
HK1032741B (en) Novel method of treatment using a high dosage regimen of amoxycillin and potassium clavulanate
HK1052638A (en) Unit dosage comprising amoxycillin and clavulanate
ZA200108321B (en) Novel method of treatment.
HK1052640A (en) Formulation comprising amoxicillin and an organic acid

Legal Events

Date Code Title Description
UUP Utility model expired